SPP100 (Tekturna/Rasilez) reduces left ventricular hypertrophy

Latest study reveals further potential benefits of renin inhibitor in heart disease

03-Apr-2008 - Speedel welcomed promising results from the latest SPP100 (Tekturna/Rasilez) surrogate marker clinical trial which were announced by Novartis. The study results show that SPP100, the first-in-class direct renin inhibitor, has shown clinically meaningful reductions in left ventricular hypertrophy, ...

Speedel: US approval for SPP100 combined with diuretic to treat hypertension

22-Jan-2008 - Speedel Holding Ltd announced that the FDA approved a second product containing SPP100 (aliskiren) in the USA for the treatment of hypertension. The approval was announced by Novartis who is responsible for commercialisation of this first in class direct renin inhibitor. Tekturna HCT® (aliskiren ...

Speedel and Novartis win the Wall Street Journal Gold Award

26-Sep-2007 - Speedel welcomed the announcement that Speedel and Novartis have won the overall Gold Award in the seventh annual Wall Street Journal contest for Technology Innovation. This Gold Award was given to both companies for their work in discovering and developing SPP100 (aliskiren) the first direct ...

Speedel announced appointment to Management Team

18-Sep-2007 - Dr Klaus Dembowsky will Head of Speedel Experimenta, Speedel's late-stage research unit. He is a MD and PhD in physiology and has extensive experience in managing research laboratories in both Big Pharma and Biotech in Germany and the USA with Bayer, Millenium, and Ingenium Pharmaceuticals. Dr ...

Speedel Receives Major Development Milestones From Novartis

Equity participation and cash payment for Aliskiren SPP100

14-Jul-2004 - Basel and Bridgewater. The Speedel Group, a privately held biopharmaceutical company focused on cardiovascular and metabolic drug development, today announced that it has received development related milestone payments from Novartis Pharma in respect of Aliskiren (SPP 100). The payments include ...